ReviewMedComm2026
Advances in FGF/FGFR Signaling: Implications for Disease and Therapy.
Review in MedComm, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The fibroblast growth factor (FGF)/FGF receptor (FGFR) signaling, primarily comprising FGFs, FGFRs, and the co-receptor Klotho, regulates key physiological processes, including embryogenesis, tissue homeostasis, metabolism, and neurodevelopment. Dysregulation of FGF/FGFR signaling, whether resulting from pathological hyperactivation or loss-of-function, is implicated in multiple diseases such as skeletal dysplasia, metabolic disorders, cancers, and neurological disorders. Consequently, correction of causative FGF/FGFR signaling represents a promising clinical strategy. Despite the deepening understanding of the FGF/FGFR signaling, its clinical translation still faces challenges, including side effects and acquired resistance to pathway blockade, as well as safety concerns regarding FGF analogs. Herein, we provide an overview of FGF/FGFR signaling and summarize its cellular and physiological functions. We further delve into the relationship between aberrant (including hyperactivated or inactivated) FGF/FGFR signaling and diverse diseases. Additionally, we also discuss the strategies targeting the causative FGF/FGFR signaling, as well as offer new perspectives for optimizing these targeted therapies. Collectively, this review will contribute to the development of more precise strategies for the targeted regulation of dysregulated FGF/FGFR signaling.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.